Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Known-groups comparisons for the WHOQOL-BREF general facet and domain scores (n = 153)

From: Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the World Health Organization quality of life-BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients

  General Facet Physical Health Psychological Health Social Relationships Environment
n Mean (SD) P-value (effect size)* n Mean (SD) P-value (effect size)* n Mean (SD) P-value (effect size)* n Mean (SD) P-value (effect size)* n Mean (SD) P-value (effect size)*
Number of different adverse eventsa
 0–5 84 6.1 (1.7) 0.10 87 13.6 (3.1) < 0.001 (0.08) 87 14.5 (2.5) 0.47 87 16.1 (2.7) 0.37 87 15.8 (2.2) 0.81
 more than 5 66 5.6 (1.8) 66 11.8 (2.9) 66 14.2 (2.6) 66 16.4 (2.4) 66 15.9 (2.4)
Number of different adverse events with CTCAE grade 3 or 4a
 0 112 6.0 (1.8) 0.16 115 13.1 (3.1) 0.06 115 14.4 (2.4) 0.93 115 16.1 (2.6) 0.36 115 15.8 (2.3) 0.82
 1 27 6.0 (1.8) 27 12.8 (3.0) 27 14.4 (2.8) 27 16.5 (2.6)
17.1 (2.2)
27 16.0 (2.3)
 2 or more 11 4.9 (1.4) 11 10.8 (2.6) 11 14.7 (2.9) 11 16.3 (2.5) 11 16.1 (2.6)
ECOG performance scoreb            16.5 (2.3)     
 0 37 6.6 (1.5) < 0.001 (0.08) 39 15.1 (2.3) < 0.001 (0.23) 39 15.1 (2.2) 0.04 (0.04) 39 14.7 (3.5) 0.05 39 16.1 (1.8) 0.38
 1 98 5.7 (1.8) 99 12.3 (3.0) 99 14.3 (2.6) 99   99 15.9 (2.5)
 2 or more 13 4.8 (1.1) 13 10.2 (2.0) 13 13.1 (2.2) 13   13 15.1 (2.3)
Global health status/QoL EORTC QLQ-C30 score
 0–50 67 4.9 (1.5) < 0.001 (0.30) 69 10.8 (2.7) < 0.001 (0.36) 69 13.1 (2.6) < 0.001 (0.22) 69 16.0 (2.8) 0.28 69 15.1 (2.4) < 0.001 (0.10)
 more than 50 79 6.8 (1.4) 80 14.6 (2.3) 80 15.5 (1.9) 80 16.5 (2.3) 80 16.6 (2.0)
  1. Abbreviations: WHOQOL-BREF World Health Organization Quality of Life-BREF questionnaire, SD standard deviation, n number of patients who completed the questionnaire, CTCAE Common Terminology Criteria for Adverse Events, ECOG Eastern Cooperative Oncology Group, QoL quality of life, EORTC QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
  2. P-values calculated with one-way ANOVA unless stated otherwise
  3. *Effect sizes (η2) were only shown where one-way ANOVA was significant (P < 0.05).
  4. aReported adverse events: as reported at and before day 1 of the first cycle of chemotherapy
  5. bPost hoc analyses with Tukey HSD test of significant differences: for the General Facet, between ECOG 0 and 1 and also 0 and 2 or higher; for Physical Health, between all ECOG categories; for Psychological Health, between ECOG 0 and ECOG 2 or higher